Zhejiang Hisun Pharmaceutical

600267 · SSE

Public Market Listing

600267SSE

SSE primary exchange listing

Live quotes, historical charts, and market capitalization for Zhejiang Hisun Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
HyzetimibeNo recent activity
Phase 3
NPC1L1Small molecule
Atherosclerotic Cardiovascular Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$724M———report ↗

Zhejiang Hisun Pharmaceutical reported revenue of $724.42M for H1 2025.

Figures only: this period's report disclosed no narrative text

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.5B$67M——report ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$1.4B$50M——report ↗
2023-FY$1.5B—$223M$13Mreport ↗
2022-FY$1.8B—$201M—report ↗